Technical Analysis for INBX - Inhibrx, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 1.50% | |
| NR7 | Range Contraction | 1.50% | |
| Narrow Range Bar | Range Contraction | 1.50% | |
| Lower Bollinger Band Walk | Weakness | 1.50% | |
| Inside Day | Range Contraction | 1.50% | |
| Lower Bollinger Band Walk | Weakness | -0.28% | |
| Outside Day | Range Expansion | -0.28% | |
| Lower Bollinger Band Touch | Weakness | -0.28% | |
| New Downtrend | Bearish | 4.63% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | 4.63% |
| Alert | Time |
|---|---|
| Down 2 % | about 2 hours ago |
| Lower Bollinger Band Support | about 2 hours ago |
| Down 1% | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| Outside Day | about 2 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/07/2024
Inhibrx, Inc. Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.95 |
| 52 Week Low | 10.8 |
| Average Volume | 87,996 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 15.68 |
| 20-Day Moving Average | 15.44 |
| 10-Day Moving Average | 15.06 |
| Average True Range | 0.89 |
| RSI (14) | 37.89 |
| ADX | 24.86 |
| +DI | 17.59 |
| -DI | 28.64 |
| Chandelier Exit (Long, 3 ATRs) | 14.75 |
| Chandelier Exit (Short, 3 ATRs) | 14.91 |
| Upper Bollinger Bands | 17.22 |
| Lower Bollinger Band | 13.67 |
| Percent B (%b) | 0.1 |
| BandWidth | 22.96 |
| MACD Line | -0.40 |
| MACD Signal Line | -0.15 |
| MACD Histogram | -0.2505 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.65 | ||||
| Resistance 3 (R3) | 14.68 | 14.51 | 14.55 | ||
| Resistance 2 (R2) | 14.51 | 14.36 | 14.50 | 14.52 | |
| Resistance 1 (R1) | 14.28 | 14.26 | 14.19 | 14.24 | 14.48 |
| Pivot Point | 14.10 | 14.10 | 14.06 | 14.09 | 14.10 |
| Support 1 (S1) | 13.87 | 13.95 | 13.78 | 13.84 | 13.60 |
| Support 2 (S2) | 13.69 | 13.85 | 13.68 | 13.56 | |
| Support 3 (S3) | 13.46 | 13.69 | 13.53 | ||
| Support 4 (S4) | 13.43 |
